No Data
No Data
No Data
Wade Bush: Buy these biotech stocks in 2024
Entering 2024, Wedbush believes that the biotech industry should have resumed positive growth long ago, especially in small and medium-sized stocks. The company believes that companies with clinical data above key risk reduction points and strong balance sheets may be most attractive. Popular choices for Wade Bush in 2024 include Ascendis Pharma, Neurocrine Biosciences, and Sarepta Therapeutics. The researchers also looked ahead for the year ahead and put forward the industry's main ideas for 2024. These include Amgen (Amgen) and Kichi
Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
REYKJAVIK, Iceland, Nov. 6, 2023 /PRNewswire/ -- A comprehensive new study from deCODE genetics, a subsidiary of Amgen, published today in Nature Genetics, provides insights into the epidemiology and
Fed tightening is imminent, risk bubbles are leaking everywhere
For those who worry that a decade of ultra-loose monetary policy has created asset bubbles around the world, the first signs of trouble may be growing in a market with high prices. According to Bank of America strategists, including Michael Hartnett, the bubble is “bursting simultaneously” in assets including cryptocurrencies, palladium, long-term technology stocks, and other historically risky market sectors. The cooling of the speculative sector comes at a time when investors are preparing for the Fed to step up the pace of policy tightening. “Reduced liquidity from the Federal Reserve will lead to higher stock risk premiums and interest rates
Listen! The sound of the bursting of the risky asset bubble is sounding.
Original title: listen! The sound of the bursting of the risky asset bubble is coming from: Wall Street is easy to fall, and all kinds of growth assets that once rose in the east wind of the Federal Reserve are now accompanied by the coming interest rate shock. is gradually returning to the normal value track. The yield on 10-year Treasuries surged 29 basis points to about 1.8 per cent this week, the highest level since January 2020. Us risky assets bear the brunt of high-growth US technology stocks, biological stocks, and new energy stocks, while digital currency assets are also doomed to be sold off.
DJIA Slides 151 pts or 0.4%; Mkt Fears Fed May Move Up QE Taper
U.S. stocks retreated as the country's last week's initial jobless claims dropped to 18-month low, inducing the market's apprehension over the potential for the Federal Reserve to begin tapering the Q
No Data